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ABSTRACT  
Brinzolamide is inhibitor of carbonic anhydride and is highly specific and non-competitive. The aim of the present study is to develop a simple, 
precise, accurate, sensitive RP-HPLC method for the determination of bulk drug. The objective of the method validation is to demonstrate 
whether the method was suited for the intended purpose. The method was validated as per the ICH guidelines. The method was validated for 
linearity, precision (repeatability, intermediate precision), accuracy, specificity, robustness, ruggedness, limit of detection and limit of 
quantification. Cosmosil (4.6X250mm, 5 μ) column was used for separation. The selected wavelength for Brinzolamide was 254 nm. The mobile 
phase consists of Acetonitrile: Potassium dihydrogen phosphate buffer (40:60). Flow rate was delivered at 1.0 mL/min. Appropriate dilutions of 
standard stock solutions were prepared to get desired concentrations in the range of 100-500 mcg/ml. The equation od standard curve was y = 
441.8x + 1132 and R2 = 0.998. The RT obtained was 6.6167 minutes. 
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INTRODUCTION: 
Brinzolamide is inhibitor of carbonic anhydride and is highly 
specific and non-competitive. Chemically Brinzolamide is 
(4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-
2H,3H,4H-1λ⁶-thieno[3,2-e] [1,2]thiazine-6-sulfonamide. 
Carbonic anhydrase is a type of enzyme that can be found in 
several body tissues including eye. It is responsible for 
catalysation of the reversible reaction indulged in carbon 
dioxide hydration and carbonic acid dehydration. In human 
beings, carbonic anhydrase is present in form of various 
isoenzymes among which the most active one is carbonic 
anhydrase II. During the ciliary processes of eye when 
carbonic anhydrase is inhibited it results in reduction of 
secretion of aqueous humour, most probably by decreasing 
the creation of bicarbonate ions with further decrease in 
transportation of sodium and fluid. This result in decrease of 
intraocular pressure.  
Literature review suggest few HPLC ,HPTLC, spectroscopic , 
Stability indicating HPLC determinations were performed.1-13 
The aim of the present study is to develop a simple, precise, 
accurate, sensitive HPLC method for the determination. 
After, doing in depth study in the present research work, it 
was found that the present research work is having various 
advantages over the previous work. The advantages include 
less retention times of the component, with good resolution. 
The % RSD of robustness was found to be less. The results 
obtained from the validation suggest that the method was 
found to be precise, accurate, linear and robust enough and 
the method was also found to be economical. 
 
 
Figure 1: Sturucture of Brinzolamide 
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EXPERIMENTAL WORK: 
Chemicals and reagents: HPLC grade acetonitrile, 
methanol, from Spectro Chemie. Ammonium acetate, acetic 
acid of analytical grade was used. Millipore grade water was 
used. The reference standard samples of Brinzolamide was 
provided was provided by Ajanta Pharma.  
Instrumentation and analytical conditions:  
The analysis was carried out by using Younglin (S.K) 
Gradient System UV Detector, 4.6X250mm cosmosil column, 
20ml loop size HPLC (With UV/Vis Detector. Other 
instrumentation includes Double beam UV- Visible 
spectrophotometer Simadzu UV-1800, digital balance 
(metler tolado), vacuum pump (Gelman science), pH meter 
(poloman). 
Chromatographic conditions: 
Cosmosil (4.6X250mm, 5 μ) column was used for separation.  
Preparation of Standard stock solution:  
100 mg of Brinzolamide was weighed in to 100 ml 
volumetric flasks. The drug was dissolved in 40 ml of solvent, 
and shaken manually for 10 min. The volume was made up to 
the mark with solvent and the final strength obtained was 
1000 µg/ml.  
Preparation of sample solution:  
1, 2, 3, 4, 5ml of the standard stock solution of Brinzolamide 
were transferred separately into five 10ml volumetric flasks 
and volume was made up to mark to get the final 
concentrations of 10, 20, 30, 40, 50µg/ml of Brinzolamide. 
The chromatograms were recorded and a standard curve 
was plotted by taking concentrations on x-axis and area 
under curve on y-axis. The equation of standard curve was 
generated to determine the concentration of drug in pure 
and degradation products. 
Validation procedure: 
The objective of the method validation is to demonstrate 
whether the method was suited for the intended purpose. 
The method was validated as per the ICH guidelines. The 
method was validated for linearity, precision (repeatability, 
intermediate precision), accuracy, specificity, robustness, 
ruggedness, limit of detection, limit of quantification. A 
calibration graph was constructed by taking six different 
concentrations, ranging from 50 – 150 μg/mL. The peak area 
was calculated, and calibration curve was constructed by 
taking peak area and concentration on both the axis. The 
linearity was evaluated by linear regression analysis. The 
precision studies were demonstrated by two parameters 
inter day and intraday precision. Intraday precision was 
performed by injecting six replicated injections to the 
chromatographic system on the same day and calculated the 
%RSD. The inter day precision was performed by injecting 
six replicated injections at two consecutive days. From the 
peak area of the chromatograms, the %RSD was calculated. 
The accuracy was determined by adding a known amount of 
the standard to the sample, and the percentage recovery was 
estimated. The robustness was determined by incorporating 
deliberate changes into the method conditions like the 
change in flow rate, pH, and gradient. Ruggedness was 
performed by carrying out the proposed method with two 
different analysts.  
RESULTS AND DISCUSSION:  
Selection of wavelength:  
UV spectrum was obtained by preparing a solution by taking 
diluents and scanned between 200 to 400 nm. Brinzolamide 
shows λmax at 254 nm. So, it is selected as a detection 
wavelength.
  
 
Figure 2: Spectrum of Brinzolamide 
 
Development and optimization of the HPLC method:  
For getting an optimized chromatographic condition, A 
Cosmosil (4.6X250mm, 5 μ) column was used for separation. 
The mobile phase consists of Acetonitrile: Potassium 
dihydrogen phosphate buffer (40:60). Flow rate was 
delivered at 1.0 mL/min with detection wavelength at 254 
nm. A 20 μL was injected to the chromatographic system 
with ambient temperature. Acetonitrile: Potassium 
dihydrogen phosphate buffer (40:60) was the optimized 
mobile phase selected for experimentation. The RT obtained 
was 6.6167 minutes.  
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Figure 3: RT of Brinzolamide 
 
Method validation: 
Linearity:  
Appropriate dilutions of standard stock solutions were 
prepared to get desired concentrations in the range of 100-
500 mcg/ml. Then the concentrations were plotted against 
the area under curves to get the equation of standard curve, 
as presented in Table 1. 
  
Table 1: Dilutions for linearity study 
Stock solution 
(µl) 
Diluted (ml) Final 
concentration 
100 10 10 
200 10 20 
300 10 30 
400 10 40 
500 10 50 
 
 
Figure 4: Standard curve of Brinzolamide 
Table 2: Linearity Data 
S. N. Conc. in (µg/ml) Mean AUC (n = 5) % RSD 
1 10 5236 0.453 
2 20 10113 0.243 
3 30 14705 0.428 
4 40 18999 0.651 
5 50 22884 0.766 
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Precision: 
Precision is determined at two levels: a) Repeatbility b) Intraday and Interday Precision. 
Table 3: Precision Data 
Parameter Amount taken (µg/ml) Amount found* (µg/ml) %RSD 
System Precision 60 59.94 0.475 
Method Precision 60 60.15 0.683 
*Mean of Six observations 
Table 4: Intraday  and Interday Precision Data 
Concentration of Brinzolamide Intraday* %RSD Interday * %RSD 
20µg/ml 20.07 0.083 19.92 0.138 
40µg/ml 39.99 0.091 39.94 0.129 
60 µg/ml 60.09 0.074 59.91 0.144 
*Mean of three observations 
Accuracy: 
To check the accuracy of the developed methods, analytical recovery experiment was carried out by standard addition method. 
Recovery study was performed by adding 80, 100 and 120 % of the test concentration as per ICH guidelines. 
Table 5: Accuracy 
Sr. No. 
Concentration of Drug 
Added (µg/ml) 
Concentration of Drug 
Added (µg/ml) 
%    Recovery±  SD 
1 64 10.4 99.99  ± 0.006 
2 80 13 99.96  ± 0.018 
3 96 15.6 96.95  ±0.027 
 
 
Limit of Quantification (LOQ) and Limit of Detection 
(LOD):  
The limit of quantification (LOQ) is defined as the lower 
concentration of an analyte in a sample that can be 
determined with acceptable precision and accuracy under 
the stated operational conditions of the method. The limit of 
detection (LOD) is defined as the lowest concentration of an 
analyte in a sample that can be detected, not quantified. The 
LOD and LOQ were estimated from the set of 5 calibration 
curves used to determine method linearity. The LOD and 
LOQ were calculated using following formula 
LOD = 3.3× σ/S 
LOQ= 10× σ/S 
Where, σ = Standard deviation of the Y- intercepts of the 5 
calibration curves, S = Mean slope of the 5 calibration curves. 
The LOQ and LOD parameters of Brinzolamide are provided 
in Table 5. 
Table 6: LOD and LOQ parameters 
Parameter Values 
S.D. of Intercept* 0.531037 
Mean Slope of Calibration Curve* 441.8 
LOD (μg/ml) 0.00396 
LOQ (μg/ml) 0.01202 
Robustness: 
Robustness was studied by observing the change in 
following parameters, and then observation of each 
parameter change was done to access their effect on system 
suitability and assay. Change in mobile phase composition 
was done by ± 5.0 ml of organic solvent and the change in 
the detection wavelength ± 10 nm was done. 
Change in mobile phase composition: The sample solution 
at test concentration (60μg/ml of drug was injected thrice 
with the mobile phase composition changed by ± 5.0ml of 
organic solvent from the developed method.  
Change in detection wavelength: The sample solution at 
test concentration (60μg/ml of drug was injected thrice with 
the change in detection wavelength by ± 10 nm from the 
developed method. The % assay of drug after changes in 
method parameters were observed. 
CONCLUSION: 
A precise RP – HPLC method was developed for the 
determination of Brinzolamide. The shorter run time elutes 
Erlotinib hydrochloride with good resolution, and 
symmetry. The method was validated as per the ICH 
guidelines and the method was found to be simple, precise, 
linear, accurate, rugged and robust enough. 
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Table 7: Summary of Validation parameters 
Parameters Brinzolamide 
Accuracy  98.95 ±0.427– 99.93 ± 0.226 
Precision (%RSD) 
System Precision 0.475 
Method Precision 0.683 
Intra-day (n = 3) 0.074 - 0.091 
Inter-day (n = 3) 0.129 - 0.144 
LOD and LOQ 
LOD 0.00396 
LOQ 0.01202 
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